GE Healthcare launches macrocyclic agent Clariscan in Europe

GE Healthcare has announced the launch of a new gadolinium-based contrast agent called Clariscan in Europe.

The macrocyclic agent Clariscan is the latest addition to the company's range of magnetic resonance imaging (MRI) contrast media options, and is designed to support effective visualisation of abnormalities in the brain, spine and associated tissues.

It will be made available at a range of doses in vials and pre-filled syringes and will complement the company's existing linear agent Omniscan, which has been used in routine diagnostic practice for over 25 years, with more than 80 million administrations to date.

Gadolinium-based agents such as Clariscan have been shown to offer improved contrast between normal and pathological tissue to enable rapid detection of abnormalities, and have therefore become a gold-standard detection tool for MRI applications.

Emmanuel Ligner, general manager of core imaging for GE Healthcare Life Sciences, said: "We believe macrocyclic Clariscan, manufactured using a proprietary GE process, extends choice for radiology professionals, backed by the well-established quality, reliability and surrounding services GE customers have come to expect."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.